• Nexopore is a wireless radiofrequency-based electroporation delivery technology for nucleic acid therapies (NATs)
  • It could improve access to these transformative treatments for the 300 million people living with genetic disorders
  • The benchtop system uses wireless electroporation (WEP) to induce pores in cells, enabling local uptake of therapeutic molecules
  • The consortium comprises HHC Medical (Denmark), Caszyme (Lithuania) and AlveoliX (Switzerland)

 

Copenhagen/Vilnius/Berne, June 10 2026: A European consortium has been awarded Eurostars funding for WiFIX, a project that aims to overcome the current delivery challenges holding back widespread adoption of nucleic acid therapeutics. It brings together in-depth complementary expertise: HHC Medical’s electroporation technology, Caszyme’s CRISPR toolkit, and AlveoliX’s organ-on-chip testbed – and showcases Europe’s innovation in the rapidly growing area of nucleic acid therapeutics.

The impact of NAT’s is limited by a translational gap: safe, efficient, and targeted delivery of these transformative treatments to the right cells. 45% of recent clinical trials held in NAT reported adeno-associated virus (AAV) safety issues, and 35% of AAV trials reported serious adverse effects due to delivery-related issues.

Electroporation is a robust transfection system dating back to the 1960s, but this new wireless version is novel. HHC Medical’s CEO and co-founder Niels Jerichau Clausen believes WiFIX could lead to universal adoption of NATs:

“For researchers and developers, current tools (viral vectors, LNPs, galvanic electroporation) impose safety, scalability, or functional limits and drive costly transitions from laboratory to clinic. Therefore, we are delighted to receive this Eurostars grant and looking forward to working with our partners to deliver Nexopore. This could improve access to the latest therapies for the 300 million people with genetic disorders.”

As one of the leading developers of CRISPR Cas gene editing solutions Caszyme also understands the need for improved delivery systems. CEO Giedrius Gasiūnas commented:

“This is an exciting project. Wireless electroporation provides enhanced delivery specificity and eliminates immunogenicity risks, improving the safety profile of gene therapies. We envision Nexopore changing the therapeutic delivery paradigm by enabling in vivo delivery without the use of proprietary buffers, nanoparticles, or viral vectors. Our task now is to present a fully functional prototype device compatible with CRISPR-Cas cargo delivery.”

Reducing reliance on animal testing represents an ongoing and strategic shift across multiple sectors. AlveoliX offers a unique organ-on-chip platform capable of mimicking a wide range of human organs in vitro, including advanced barrier models and an AXLiver-on-Chip model currently under development. This technology is used for safety and efficacy assessment as well as for fundamental research, providing human‑relevant insights across multiple applications. Within the WiFIX project, such capabilities offer clear added value, as highlighted by Nina Hobi, CEO of AlveoliX:

“Human‑relevant in vitro models are key to bridge the gap between laboratory research and clinical translation. Our technology helps de‑risk gene‑editing approaches at an early stage while significantly reducing reliance on animal models.”

The project is scheduled for completion in March 2028.

Media contact:

HHC Medical
Niels Jerichau Clausen
E: nc@hhc-medical.com

Caszyme
Richard Hayhurst
T: +44 7711 821527
E: Richard.hayhurst@59north.bio

AlveoliX
Pauline Zamprogno
E: pauline.zamprogno@alveolix.com

About:

HHC Medical is a Danish health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Our groundbreaking platform targets precise areas within the body, making it possible to deliver localized genetic therapies previously deemed unattainable. This revolutionary approach has the potential to redefine the delivery of genetic medicine, unlocking new avenues of patient care on a global scale. www.hhc-medical.com

Caszyme is a Lithuanian gene editing company which combines its deep experience and dynamic platform to deliver world class CRISPR solutions. Caszyme was established in 2017 by pioneers of CRISPR-Cas gene editing research. Over the last 9 years, Caszyme has rapidly advanced its excellence and capabilities as an enabling expert partner in CRISPR gene editing solutions, collaborating with multiple life science organizations aiming to enter the CRISPR field or expand their gene editing capabilities. Company has a long-term expertise in discovery and development of novel gene editing tools, proteins evolution and engineering, mRNA synthesis and optimization. Also Caszyme has developed a platform of unique CRISPR Cas12l nucleases. This enables Caszyme and its partners across various industries to effectively apply CRISPR gene editing technology and tools for their market-ready products. www.caszyme.com

AlveoliX is a Swiss biotech company that provides advanced in vitro solutions based on proprietary organ-on-chip technologies designed to replicate key aspects of human organ physiology. These platforms enhance the predictive accuracy of preclinical decision-making, reduce development timelines and costs, and support the transition away from animal testing. While widely used in drug discovery and development, AlveoliX’s solutions are also applicable across a broad range of fields, including nutrition, cosmetics, chemical and environmental safety, as well as precision medicine and rare disease research. www.alveolix.com